DEF: bioAffinity Technologies Seeks Shareholder Approval for Key Proposals
Proxy Statement
bioAffinity Technologies is convening a Special Meeting of Stockholders on November 20, 2026, to vote on several proposals, including warrant exercises, potential future offerings, and a reduction in authorized shares.
Summary
- bioAffinity Technologies is holding a Special Meeting of Stockholders on November 20, 2026, to vote on five key proposals.
- The proposals include approving the issuance of shares upon the exercise of warrants from two recent private placements (August 2026 and October 2026).
- Stockholders will also vote on authorizing the company to issue securities in future non-public offerings, up to 10,000,000 shares with a total consideration not exceeding $15,000,000.
- A proposal to reduce the total number of authorized common stock shares from 350,000,000 to 200,000,000 will be presented.
- The meeting also includes a proposal to adjourn if necessary to secure sufficient votes for the other proposals.
- The company's CEO, Maria Zannes, highlights progress in developing noninvasive diagnostics for lung cancer with the CyPath Lung test.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily focused on necessary corporate actions to facilitate future growth and Nasdaq compliance, rather than immediate financial performance.
Positives
- The company is actively seeking shareholder approval for actions that could enable future capital raises and support its business strategy.
- The proposed reduction in authorized shares may be viewed positively by investors as it limits potential future dilution.
- The company is progressing with its core mission of developing noninvasive diagnostics for lung cancer, with its CyPath Lung test seeing growing adoption.
- The Board of Directors unanimously recommends voting FOR all five proposals, indicating internal alignment on these strategic moves.
Negatives
- The approval of warrant exercises (Proposals 1 and 2) will lead to dilution of existing stockholders' ownership interests.
- The potential issuance of up to 10,000,000 shares in future offerings (Proposal 3) also carries significant dilution risk for current shareholders.
- The company is seeking authorization for future offerings without specific terms defined, creating uncertainty about the exact impact on share price and ownership.
- The potential sale of a large block of shares in future offerings could concentrate voting power in the hands of a few investors.
Risks
- The sale of shares upon exercise of warrants and in future offerings could materially and adversely affect the market price of the Company's Common Stock.
- If Proposal No. 1 is not approved, the company may incur substantial additional costs and expenses and lose potential proceeds from warrant exercises.
- If Proposal No. 2 is not approved, the company may incur substantial additional costs and expenses and lose potential proceeds from warrant exercises.
- The potential issuance of securities in non-public offerings could dilute the voting power of existing shareholders, potentially deterring a takeover.
- The company's ability to fund operations could be adversely impacted if potential funds from warrant exercises are not realized due to lack of shareholder approval.
Future Outlook
The company is seeking authorization for future capital raises of up to $15,000,000 through non-public offerings, subject to Nasdaq rules and Board discretion, with offerings to occur on or before November 20, 2027. The reduction in authorized shares aims to make investment more attractive by limiting future dilution.
Management Comments
- "I am pleased to invite you to attend a Special Meeting of Stockholders (the Special Meeting) of bioAffinity Technologies, Inc. (the Company or bioAffinity Technologies) on Friday, November 20, 2026, at 8:00 a.m. Central Time."
- "bioAffinity Technologies is committed to developing noninvasive diagnostics for lung cancer and other diseases of the lung."
- "Our team of scientists and business professionals is driven by its mission to increase detection of cancer at early stage when accurate diagnosis leads to longer lives, fewer unnecessary invasive procedures, reduced patient anxiety, and lower medical costs."
- "I am greatly encouraged by the growing adoption and use by physicians of our first test, CyPath Lung, a noninvasive test for lung cancer, and of the technological advancements that our team continues to make in its fight to address the urgent need for noninvasive, early-stage diagnosis."
- "Whether or not you plan to attend the Special Meeting, your vote matters. We encourage you to promptly vote your shares by proxy over the internet, via telephone or by mail."
- "Your trust in our team and belief in our technology are invaluable."
- "On behalf of our Board of Directors, our executive leadership team, and our dedicated team of scientists and businesspeople, we extend our sincerest gratitude for your continued support of and investment in bioAffinity Technologies."
Industry Context
StockSavvy.ai notes that bioAffinity Technologies operates in the competitive and rapidly evolving field of medical diagnostics, specifically focusing on early-stage cancer detection. The company's strategy involves leveraging technology to create non-invasive tests, addressing a significant unmet need in the market. The proposals in this filing are typical for a growth-stage biotech company seeking to maintain Nasdaq compliance, manage its capital structure, and position itself for future funding rounds.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Amendment to Certificate of Incorporation | Proposal to reduce the total number of authorized shares of common stock from 350,000,000 to 200,000,000. | Upon filing with Delaware Secretary of State (if approved and implemented by Board) | May make investment more attractive to investors by limiting the risk of future dilution. The Board retains discretion to delay or abandon the decrease. |
Stakeholder Impact
- Shareholders will experience dilution in their ownership interests upon the exercise of warrants and potential future issuance of securities.
- Shareholders' voting power may be diluted by the issuance of new shares.
- The potential concentration of voting power in a few investors could influence future corporate decisions.
- The company's ability to fund operations and pursue its business strategy is dependent on successful capital raises and warrant exercises, impacting all stakeholders.
Next Steps
- Stockholders are encouraged to vote their shares by proxy via the internet, telephone, or mail.
- The Special Meeting will be held on November 20, 2026, at 8:00 a.m. Central Time.
- The company will prepare and file a registration statement for the resale of shares underlying the August 2026 Warrants and Pre-Funded Warrants.
- The company will prepare and file a registration statement for the resale of shares underlying the October 2026 Common Warrants.
- The Board will implement the decrease in authorized shares only upon a determination that it is in the best interests of stockholders.
- The company may adjourn the Special Meeting if necessary to solicit additional votes for the proposals.
Key Dates
| Date | Description |
|---|---|
| 2026-08-14 | Closing date of the private placement offering for August 2026 Common Warrants. |
| 2026-09-23 | Record date for determining stockholders entitled to notice of and to vote at the Special Meeting. |
| 2026-10-08 | Closing date of the private placement offering for October 2026 Common Warrants. |
| 2026-10-23 | Date of the letter to stockholders and mailing date for the Notice of Internet Availability of Proxy Materials. |
| 2026-11-17 | Deadline for stockholder proposals intended for inclusion in the 2027 Annual Meeting proxy statement. |
| 2026-11-19 | Deadline for internet and telephone voting for the Special Meeting. |
| 2026-11-20 | Date of the Special Meeting of Stockholders. |
| 2027-01-30 | Latest date for stockholder notice for business to be brought before the 2027 Annual Meeting (under certain conditions). |
Recommendation
holdThe filing is primarily procedural, seeking shareholder approval for necessary corporate actions related to Nasdaq compliance and future capital flexibility. While the company is advancing its core technology, the proposals themselves involve potential dilution and do not present immediate financial performance indicators. Therefore, a 'hold' recommendation is appropriate pending further developments and clarity on the impact of these proposals.
Keywords
Special Meeting, Stockholder Approval, Warrant Exercise, Authorized Shares, Nasdaq Compliance, Private Placement, Capital Raise, Lung Cancer Diagnostics
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.